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INTROD UCTIO
Over the past several years , a number of ca rd io vasc ular preparations have
become widely used in psychiatry. For example , propranolol , int roduced for its
anti-anginal properties, is now used fo r stage-fright, lithium tremor a nd ne uro-
leptic induced akath isia (1,2). Calcium channel b lockers are e xpecte d to prove
use ful in the treatment of bipol ar affective d isorders (3,4) .
C lonidine exemplifies the rapidity and variety with whi ch a ca rdiovascu lar
agent has been applied to psychiatric syndromes. Clonidine , a ce ntra lly acting
anti-h ypertensive drug with both alpha-l and alpha-2 ad rene rgic agonistic
properties, has a lready been used in the treatment o f narcotic withd rawal,
benzodiazepine withdrawal , Tourette's syndrome , a ka th isia, d epression ,
chro nic schizophrenia and acute mania, as well as in tardive dyskinesia ( 1,5,6).
T he therapeutic effectiveness of clonidine in tardive dyskinesia was in itiall y
reported by Freedman and co -workers and by Nishikawa and co -wor ke rs (7,8) .
Tardive dyskinesia is a term applied to a group of involuntary movement
disorders usually involving the oro-facial region , but also affecting lim bs and
trunk. This disorder, on average reversible in ov er one-third of all patien ts in
whom ne uroleptics are d iscontinued (9), is a persistent neurologic comp lication
induced by longterm neuroleptic treatment. Nishikawa a nd co-wor ke rs treated
29 such patients wit h c1onidine; results at 4 years follow up showed th at 75
percent showed at least moderate improvement; full resolution occu rred in 50
percent of the cases (10). Onset of improvement occurred wit h in 3 to 7 days of
initiating clonidine treatmen t. The present com m un ica tion reports an addi-
tional case in which videotapes documented th e movement di sorder before and
d ur ing clonidine treatment. Abrupt cessation of clonidine resu lted in en ha nced
dys kinetic movemen ts.
CASE REPO RT
The patient is a 29 year old white single stu dent admitted voluntar ily to a
psychiatric hospita l after three da ys of auditory a nd visual hallucin ati ons and
vague fee lings of depersonalization . The patient 's fir st co ntact with psychia try
occurred 5 years previously wh en he was diagnosed as being " psychot ica lly
depressed" with symptoms of deperso na lizat ion a nd derealization. The present
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admission was his fifth psychiatric hospitalization. He had been treated with a
variety of antipsychotics; three years prior to admission he was stabili zed on 10
mg of thiothixene per day. This was discontinued one year prior to ad m ission.
However, three months prior to admission he was restarted on th iothixe ne at
doses ranging from 15 mg to 40 mg per da y as a result of re-emergence of
psychotic symptoms. The case was further complicated by th e prese nce of
complex partial seizures, which were reported to have occurred 2-3 t imes a
week; electroencephalogram showed paroxsymal bursts of diffuse theta waves.
According to his mother, abnormal movements o f th e upper ex tremities,
facial grimacing, and tic-like movements had become obvious six months prio r
to admission. The movements were continuous and not se izure related. O nce
the diagnosis of tardive dyskinesia was suspected, the doses o f thiothixene were
gradually decreased. The patient had abused numerous substances, includi ng
coc aine , LSD, alcohol and marijuana since adolescence. There was no curre nt
substance abuse. It is important to note that the patient 's brother was also tak in g
antipsychotic medication. He also exhibited a movement disorder charac te r ized
by dystonic posturing, but refused further neuropsychiatric e va lua t ion of th ese
movements.
Initially the patient exh ib ite d a mildly constricted affect with dysphoric
mood. His speech was coherent, although digressive . He described fee lings of
derealization and depersonalization; there were no hallucinations or di sruptive
behaviors. The patient 's general ph ysical and neurologic exam was nor ma l
(aside from abnormal movements). Neither hypotonia nor incoordinati o n was
present. He was noted to have co ntinuous stereo typed invo luntary choreoa the-
toid movements in the upper extrerneties including gr imacing and bucco-l ingual
masticatory movements. Blood chemistries were within normal limits, inclu di ng
normal thyroid function tests. A magnetic resonance scan was no rmal.
Repeat electroencephalography showed generalized th eta wave slowing.
Differential diagnostic possibilities that were ruled out included Huntingto n 's
chorea, Tourettes syndrome, amphetamine intoxicati on , brain tumor and
torsion dystonia. The consulting neurologist co nfir med th e diagnosis of tard ive
dyskinesia. The consultant also recommended an e mp ir ica l tri al of a nti-
convulsants because the psychic symptomatology in conjunction with th e non-
specific EEG abnormalities were so suggestive of complex partial seizures. The
patient was thus treated with valproic acid.
The patient's thiothixene was gradually reduced to 5 mg once dail y. At this
point the patient's movements were videotaped. Clonidine 0.1 milligram twice
daily was initiated. Thereafter on every second da y, clonidine was increased by a
tenth of a milligram and thiothixene was decreased by one milligram a day. The
dosage of clonidine was stabilized at 0.5 milligrams a day, in part because
postural hypotension developed at this point. Thiothixene was th en di scont in-
ued . After three da ys on this dosage, repeat videotaping and a repeat A IMS
rating was done. Significant clinical improvement was noted. T able One shows
the blind ratings by two observers and AIMS scores (11) (don e by two treat ing
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physician s) obtained befo re t reatment was initiated, after three days of treat-
ment and after 10 days of treatment. The patient was discharged, but rehospita l-
ized three weeks la te r after having abruptly discontinued all hi s medicat io ns.
The "after cessation" co lumn on Table I shows the AIMS ratings for his
movement disorder at that time. H e refused to be videotaped, but th e treating
physicians rated his movements as having returned to pre-treatment levels of
severity .
T he patient refused further treatment of h is movement di sorder or
clonidine treatment. H oweve r , he did continue to take valproic ac id whi ch had
been started for his complex partial seizures, a total of 1250 milligrams in
divided doses.
DISCUSSION
Accurate d iagnosis is the first problem in any study of th e treatment of
tardive dyskinesia. T he d iffer en tial diagnosis is extensive and includes Hunting-
ton's chorea, Tourette 's syndrome, L-dopa induced chorea , se nile chorea,
Wi lson's d isease, torsion dystonia , viral encephalitis and amphetamine intoxica-
tion. Also, in the absence ofa history of exposure to a nti-psychot ic medication or
neuroleptics used as antiemetics, there does not appear to be , as yet, any
biochemica l or clin ical way to establish whether a choreiform or dystonic
movement is " ta rdive" or is a refl ectio n of a primary neurologic disorder (12). A
further complication is that on the average tardive dyskinesia is reve rsible in
only a third of all patients in whom neurolept ics are dis continued and tends to
T A BLE 1.
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and After Treatment o f CIonidine
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TP I and TP 2 = Treating Psychiatrists aware of treatment status who rat ed th e pa tients
using the A IMS schedule.
CN I and CN 2 = Consulting Neurologists blind to treatment status who ra ted
videotapes.
A IMS sco res are summed fro m 9 specific observations, ea ch sca led 0 to 4; 0 (no ne) , I
(minima l), 2 (mi ld), 3 (moderate) , and 4 (severe).
Blind global ratings (BG R) by consulting ne urologists are scaled; 4 (extrem ely severe), 3
(moderately severe), 2 (moderate), I (mi ld) and 0 (absent).
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persist at an even level of severity in the remaining two-thirds of the patients
(9).
In this case, the presence of an affected sibling and EEG abnormalities
caused us to suspect the possibility of a primary rather than drug-re la ted
movement disorder. However, consultants viewing th e vid eotapes have diag-
nosed tardive dyskinesia uniformly. We also considered the possibil ity that the
patient's AIMS scores improved because of neuroleptic withdrawal rather th a n
the use of clonidine; however, the rapid time course of improvement and the
return of abnormal movements once clonidine was withdrawn argue against th is
explanation .
Tardive dyskinesia is thought to result from chronic blockade of receptors
by neuroleptics leading to supersensitization of post synaptic striatal dopam ine
receptors (13). Neuroleptics block dopamine receptors thus preventin g dopa-
mine from acting on post-synaptic neurons. The post-synaptic ce ll responds to
this blockade by making new dopamine receptors, after whi ch th e ce ll becomes
supersensitive to dopamine. This supersensitivity is said to relate to tard ive
dyskinesia; however, nothing in this hypothesis explains wh y only a few patie nts
subjected to long term dopamine receptor block ade develop dyskinetic move-
ments. The hypothesis does predict, however, that wh en receptors are
unblocked, for example when neuroleptics are discontinued, post-syn aptic cells
will have an increased response and choreiform or dystonic movements will
appear or increase. This is consistent with clinical observations, such as the very
typical onset after discontinuation of medication (14,15), as occur red in this
case. If doses of neuroleptics are increased, the new receptors are blocked and
tardive dyskinesia will abate temporarily.
A more recent hypothesis proposes that noradrenergic as well as dopamin-
ergic overactivity is important in tardive dyskinesia (10) . Clonidine in low doses
appears to have anti-noradrenergic effects reducing noradrenergic function by
stimulating pre-synaptic noradrenergic neurons, which ultimately down-regu-
lates th e noradrenergic axis as receptors decrease. The doses of clonidine used
in this study and by Nishikawa and coworkers (10) were com parable to low doses
used in the treatment of hypertension. Similarly, the three da y delay in onset
and in improvement of tardive dyskinesia after clonidine was started pa rall e ls
the one to three day interval before anti-hypertensive effects are seen whe n
clonidine is used for hypertension . These parallels suggest that clonidine may act
in tardive dyskinesia, as has been postulated for its action in hypertension , by
down-regulating noradrenergic transmission.
CONCLUSION
Previous reports indicate that over fift y percent of cases of tardive d yskine-
sia respond with improvement to treatment with th e alpha noradrenergic
agonist, clonidine. This report adds another case in which both rapid improve-
ment on initiation and rapid exacerbation on discontinuation of clonid ine
CLONIDINE IN THE TREATMENT OF TARDIVE DYSKI N ESIA 25
treatment were documented. The postulated mechanism of acti on of c1onid-
ine-down-regulation of noradrenergic activity by decreasing fu nc t iona l recep-
tor supersensitivity-meshes with the postulated mechanism fo r tardi ve dysk i-
nesia , receptor supersensitivity. Clonidine has an advantag e ove r some other
agents used to treat tardive dyskinesia, in that it has few sid e e ffec ts. Postural
hypotension , the major side effect in our experience , usually ca n be controlled
by stabilizing the dosage, as in this case, because e ven low dosages are effec tive in
decreasing abnormal movements.
Discontinuation of neuroleptics or lowering th e dosage as much as clini-
cally possible remains the mainstay of treatment of tardive dysk inesia. T h is case
illustrates the importance of some of the measures recommended for preve nti on
of tardive dyskinesia: 1) use of neuroleptics only when th ere is a specific
indication and 2) th e need to consid er dis continuation of neuroleptics when
target symptoms do not respond after six months.
However, as in this case, there is a role for treatments whi ch reduce the
se ve r ity of the movement disorder, even when withdrawal of neuroleptics is the
major intervention . Even in those patients who respond to neuroleptic with-
drawal, abnormal movements ma y persist.
Because tardive dyskinesia has a high prevalence (15-20% of those ex posed
to a neuroleptic agent for more than one year) and a high incidence (2- 5% fo r
the first few years of neuroleptic maintenance) (16), there is need fo r more
research on treatment methods in this disorder. No treatment to date uniformly
benefits dyskinesias in all patients (17). The work to date with clo nid ine indicat es
that finding effective new treatments ca n also give clu es as to the ba sic biology o f
the disorder.
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